Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 3:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 85,759 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Blasts 10 Percent or More of Peripheral Blood White Cells, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
Cladribine, Cytarabine, Gilteritinib, Idarubicin, Laboratory Biomarker Analysis, Midostaurin, Venetoclax
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
GERD, Barrett's Esophagus
Interventions
Fluorescein, Proflavine hemisulfate
Drug
Lead sponsor
Anandasabapathy, Sharmila, M.D.
Individual
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Completed Phase 3 Interventional Results available

The Effect Of Oral Ibandronate In Male Osteoporosis

NCT00397839
Conditions
Male Osteoporosis
Interventions
Ibandronate, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
30 Years and older · Male only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 36 more
Conditions
Colon Cancer, Rectal Cancer
Interventions
Cetuximab, Irinotecan, IMC-A12 (cixutumumab)
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Vallejo, California • Greenville, North Carolina • Scranton, Pennsylvania
Conditions
Diabetes, Type 2
Interventions
Community Health Worker Diabetes Education: Print media, CHW Diabetes Education: tailored web site
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Completed Not applicable Interventional Accepts healthy volunteers

Creating Access to Resources and Economic Support

NCT05971160
Conditions
Psychological Distress
Interventions
Financial education videos, Microgrant, Peer mentoring
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Schizophrenia
Interventions
Clinical Learning Study smartphone app (i.e., the study app)
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Anaheim, California • Torrance, California • Hialeah, Florida + 4 more
Terminated Phase 2 Interventional Results available

GTX-RT in Borderline Resectable Pancreatic Cancer

NCT01754623
Conditions
Pancreatic Cancer
Interventions
Capecitabine, Gemcitabine, Docetaxel, Stereotactic body radiation therapy (SBRT), Restaging review after radiation, Surgery, 5-Fluorouracil
Drug · Radiation · Other + 1 more
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Comparison of Meperidine for Post-Cesarean Analgesia: Bolus Versus Infusion and Bolus

NCT01741259
Conditions
Cesarean Section
Interventions
Meperidine
Drug
Lead sponsor
Mercy Research
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
273 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Gastroesophageal Reflux
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Year to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Anaheim, California • Miami Garden, Florida • Kansas City, Missouri + 1 more
Conditions
Covid19
Interventions
Bardoxolone Methyl, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Springfield, Illinois • Brooklyn, New York • Elmhurst, New York + 2 more
Conditions
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, KRAS Protein Variant, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions
Cetuximab, Cisplatin, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Biological · Drug · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Leiomyoma
Interventions
BAY1002670, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
36
States / cities
Mesa, Arizona • Tucson, Arizona • San Diego, California + 29 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination

NCT04722003
Conditions
Gonorrhoea
Interventions
Meningococcal Group B Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Decatur, Georgia
Conditions
Prevention of Zika Infection, Zika-Specific Immune Response
Interventions
VRC-ZKADNA090-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 3 Interventional Results available

CRESTOR Athero Imaging Head to Head IVUS Study

NCT00620542
Conditions
Coronary Atherosclerosis
Interventions
Rosuvastatin, Atorvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
2,333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
97
States / cities
Huntsville, Alabama • Los Angeles, California • Mountain View, California + 94 more
Conditions
Asthma
Interventions
Montelukast, Prednisone
Drug
Lead sponsor
Hal C Charles
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Substance Use Disorders
Interventions
Advanced Emotion App, Basic Emotion App
Behavioral
Lead sponsor
Treatment Innovations
Industry
Eligibility
18 Years to 26 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Newton, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers

A 21 Day Pharmacokinetics Study in Papulopustular Rosacea

NCT02028286
Conditions
Papulopustular Rosacea
Interventions
CLS001
Drug
Lead sponsor
Maruho Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
2
States / cities
Hackensack, New Jersey • Austin, Texas
Completed Phase 4 Interventional Results available

Bupropion and Weight Control for Smoking Cessation - 1

NCT00006170
Conditions
Tobacco Use Disorder
Interventions
Bupropion, Placebo, weight concerns intervention, smoking cessation intervention
Drug · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Single Doses of IV Aerucin in Healthy Adults

NCT02486770
Conditions
Healthy
Interventions
Aerucin 2.0mg/kg, Aerucin 8.0mg/kg, Aerucin 20.0 mg/kg
Biological
Lead sponsor
Aridis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Immune Thrombocytopenia
Interventions
Romiplostim
Drug
Lead sponsor
Amgen
Industry
Eligibility
1 Year to 18 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
16
States / cities
Roseville, California • Atlanta, Georgia • Chicago, Illinois + 13 more
Conditions
Barrett's Esophagus, Esophageal Cancer, Intramucosal Adenocarcinoma
Interventions
Specimen Collection
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Advanced Cancer, Colorectal Cancer, Mantle Cell Lymphoma
Interventions
Ramucirumab, Merestinib, Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • Houston, Texas